Skip to content
Menu

Alamar Biosciences Announces New Research Published In JAMA That Uses Its NULISAqpcr eMTBR-Tau Single-Plex Assay To Evaluate Whether A Blood Test Could Identify CTE In Living Patients

Benzinga Newsdesk 5 hours ago

FDANews

New research published in the Journal of the American Medical Association (JAMA). Researchers at Boston University CTE Center, with collaborators at Banner Health and more than 20 Institutions, used Alamar’s NULISAqpcr™ eMTBR-tau single-plex assay to evaluate whether a blood test could identify chronic traumatic encephalopathy (CTE) pathology in living patients.

The researchers found higher blood levels of eMTBR-tau in former football players with advanced CTE and that levels rose with the amount of tau tangle pathology in the brain. eMTBR-tau is a protein fragment linked to the tau tangles seen in CTE and Alzheimer’s disease. CTE is a. neurodegenerative disease associated with repeated head impacts. Today it can only be confirmed by examining the brain after death. The finding could give researchers a way to study CTE during life.

The study included 21 former American football players who gave blood samples during life and later donated their brains for research through Boston University CTE Center Studies. Eighteen had CTE, including 16 with high-stage disease. Plasma eMTBR-tau was significantly higher in high-stage CTE than in low-stage CTE or no CTE. Five of the CTE cases also had Alzheimer’s disease, and eMTBR-tau levels were highest in people who had both conditions. The researchers also measured p-tau217, an established blood marker for Alzheimer’s disease. It was elevated only in people with Alzheimer’s pathology and was not associated with CTE. Used together, the two markers may help researchers tell the conditions apart.

The study suggests a promising new biomarker approach to accurately detecting CTE pathology through a blood test, with the potential to improve patient diagnosis, identification and enrollment in clinical trials, and support the development of targeted therapies. The researchers describe the results as an early study that requires validation in larger and diverse cohorts. The test is not a diagnostic tool and is not available for clinical use. To date, no blood test has yet been validated for diagnosing CTE in living patients.

Read at benzinga.com